Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib.
Saved in:
| Title: | Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib. |
|---|---|
| Authors: | Hu, Yuanqiong1,2 (AUTHOR), Eynikel, Dimitri1 (AUTHOR) dimitri.eynikel@msf.org, Boulet, Pascale3 (AUTHOR), Krikorian, Gaelle1 (AUTHOR) |
| Source: | Journal of Pharmaceutical Policy & Practice. 1/14/2020, Vol. 13 Issue 1, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20523211 |
|---|---|
| DOI: | 10.1186/s40545-019-0198-6 |
